Home › Stocks › Cipla vs Divi's Laboratories

Cipla vs Divi's Laboratories — which is better value?

A branded book against pure contract manufacturing. This page sets the two side by side on their filed records, what each share price assumes, and what decides each one's value.

FairStocks Research
Updated 15 Nov 2026 · 3 min read
| NSE: CIPLA NSE: DIVISLAB
On this page ▾
  1. Two businesses
  2. The records side by side
  3. What each price assumes
  4. What decides each value
  5. What could go wrong
  6. Which is better value?
  7. Related comparisons
  8. Questions
In 30 seconds

Today's prices ask more of Divi's Laboratories than of Cipla.

At current prices, buyers of Cipla are assuming about 2% growth against 7% in its own record; for Divi's Laboratories it is 31% against 8%. That shows which share needs more to go right — not which is cheaper. How far each trades from its estimated fair value is in the full valuations.

  • Valuation method: Cipla on discounted cash flow; Divi's Laboratories on estimate withheld.
  • Size: Divi's Laboratories is worth about 2.7 times Cipla on the stock market.
  • Record: Divi's Laboratories has grown revenue faster: Cipla compounded at about 8% a year (FY2018–FY2026) and Divi's Laboratories at about 13% (FY2018–FY2026).
  • What to watch: complex us generics at Cipla; custom synthesis contracts at Divi's Laboratories.
CiplaDivi's Laboratories
Price₹1,392₹11,442
Market cap₹1.12L Cr₹3.03L Cr
P/E38.890.2
P/B3.2718.09
Fair value 🔒 sign in₹0,000₹0,000
Upside 🔒 sign in+00%+00%
Valued onDiscounted cash flowEstimate withheld
See both fair values, side by sideEvery step of each working, the scenarios and the reports Free during launch →

01Two businesses

CiplaCIPLA

Ninety years of affordable medicine

Cipla was founded in 1935 by Khwaja Abdul Hamied and became known worldwide for low-cost HIV medicines in the early 2000s. Today it is one of India's largest pharmaceutical companies, with strong positions in India, South Africa and the US.

The ingredient maker behind global brands

Divi's Laboratories was founded in Hyderabad in 1990 by Dr Murali Divi. It makes active pharmaceutical ingredients (APIs) — the chemical heart of a medicine — for generic drugmakers, and runs custom synthesis for large global pharmaceutical companies, producing ingredients for their patented drugs.

02The records side by side

Divi's Laboratories has grown revenue faster: Cipla compounded at about 8% a year (FY2018–FY2026) and Divi's Laboratories at about 13% (FY2018–FY2026). By revenue, Cipla is about 2.7 times the size of Divi's Laboratories. Cipla kept 13.7% of revenue as net profit in FY2026; Divi's Laboratories kept 24.3% of revenue as net profit in FY2026 — a sign of very different business models.

Full ten-year tables and charts are on each company's page: Cipla · Divi's Laboratories.

03What each price assumes

Work backwards from each share price and you can see what buyers are taking for granted — the rate each company must sustain to justify what it costs, against what its own record supports.

Price implies
2%
growth
Record supports
7%
growth
Price implies
31%
growth
Record supports
8%
growth

04What decides each one's value

  • Complex US genericsInhalers and other hard-to-make products face less competition than simple pills.
  • India branded businessSteady, cash-rich and growing with the domestic market.
  • Custom synthesis contractsLong-term work for global innovators is the highest-value part of the business.
  • Generic API volumesPrices for generic APIs follow global supply, including from China.

05What could go wrong

  • FDA complianceInspection problems at key plants have delayed launches before.
  • US price erosionGeneric prices fall as competitors enter.
  • Chinese competitionCheaper Chinese APIs can pressure prices.
  • Customer concentrationA few large contracts matter a lot.

06Which is better value?

Cipla
Fair value per share
₹0,000
Upside
+00%
Divi's Laboratories
Fair value per share
₹0,000
Upside
+00%

Sign in free to see which trades further below its worth

  • ✓Both fair values per share — each on the method that fits the business
  • ✓Every step of both workings — growth, margins and cost of capital, with sources
  • ✓Bull, base and bear cases — for each company
  • ✓Downloadable reports — the full write-up for each, yours to keep
Free during launch · unlimited valuations · no card required

08Questions people ask

Is Cipla or Divi's Laboratories better value?

That turns on how far each share trades from its estimated fair value. Both figures, with every step of the working, are in the full valuations, free to view once you sign in. On the public numbers, Cipla trades at 38.8 times earnings and 3.27 times book value, and Divi's Laboratories at 90.2 times earnings and 18.09 times book value — but multiples alone mislead when two businesses work differently, which is why each is valued on the method that fits it.

What is the difference between Cipla and Divi's Laboratories?

Cipla was founded in 1935 by Khwaja Abdul Hamied and became known worldwide for low-cost HIV medicines in the early 2000s. Divi's Laboratories was founded in Hyderabad in 1990 by Dr Murali Divi.

Are Cipla and Divi's Laboratories valued the same way?

No. Cipla is valued on discounted cash flow and Divi's Laboratories on estimate withheld, because forcing one model onto both would misstate at least one of them.

What does today's price assume for Cipla and Divi's Laboratories?

Worked backwards from the share price, Cipla needs about 2% growth and Divi's Laboratories about 31% growth, against 7% and 8% in their own records.

About this comparison

Written by the FairStocks research team from both companies' filed accounts; figures refresh as new results are filed. Each company is valued on the method that fits it — see a fully worked example or the valuation guides. Educational research, not investment advice.

See both fair valuesUnlock free